ROCKVILLE, MD — The chief executive officer of MacroGenics made $783,000 in compensation in 2016 after making $3.9 million in 2015, according to a filing with the Securities and Exchange Commission Tuesday.
CEO Scott Koenig’s base salary of $535,000 increased 3 percent from 2015. He was paid a bonus of $240,000 in 2016. He received no stock option awards in 2016 after receiving $3.1 million in stock option awards in 2015.
The clinical stage biopharmaceutical company has a market capitalization of $600 million and focuses on the development of treatments that use the immune system to fight cancer.
Shares closed Thursday at $17.21, down 1.5 percent. The 52-week range is $16.28 to $33.30.
MacroGenics’ stock price hit a five-year low of $15.82 on Feb. 26 of last year before rebounding to a 2016 high of $31.51 on Aug. 5.
In 2016, the company initiated a Phase 1 study of its own anti-PD-1 antibody and also showed that its autoimmune-based DART molecule achieved the anticipated biological effects in a Phase 1 study.
Koenig, 64, said on the company’s fourth quarter conference call on Feb. 28, “I think it is a key takeaway for the investment community today that each of our proprietary oncology programs in the clinic has shown initial evidence of anti-tumor activity. Clearly, this is very encouraging.”
This story is from the Maryland Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism